Revion Tirzepatide Research Peptide

Revion Tirzepatide is a dual-acting GIP (Glucose-dependent Insulinotropic Polypeptide) and GLP-1 (Glucagon-Like Peptide-1) receptor agonist synthesized for high-level scientific research. As a key reference compound in metabolic studies, Tirzepatide allows researchers to evaluate the synergistic biological effects of dual incretin stimulation on insulin secretion, lipolysis, and glycemic regulation.

Each batch of Revion Tirzepatide supplied by Revion Research Lab is independently tested via HPLC and Mass Spectrometry to guarantee high chemical purity and structural fidelity.

Mechanism of Action: Dual GIP & GLP-1 Agonism

Unlike single-target peptides, Revion Tirzepatide binds to both GIP and GLP-1 receptors, mimicking natural incretin hormones while exhibiting an extended half-life optimized for ongoing experimental protocols.

GIP Receptor Pathways

• Enhances pancreatic beta-cell sensitivity to glucose.

• Influences adipocyte function and lipid storage pathways in cell culture models.

GLP-1 Receptor Pathways

• Delays gastric emptying parameters in animal trial subjects.

• Suppresses inappropriate glucagon secretion under elevated glycemic conditions.

Technical Specifications

• Compound Name: Tirzepatide

• Brand/Supplier: Revion Research Lab

• Sequence Integrity: Confirmed via HPLC analysis (≥98% purity)

• Form: Lyophilized cake/powder

• Recommended Storage: -20°C for long-term storage; 2°C–8°C post-reconstitution

Comparative Research Applications

When conducting comparative incretin studies, researchers frequently compare dual-agonist behavior against newer triple-agonist formulations.

• Dual-Agonist Reference: Use Revion Tirzepatide to establish baseline dual GIP/GLP-1 response metrics.

• Triple-Agonist Reference: Explore expanded GCG receptor stimulation options on our Revion Retatrutide Category Page or review specific dosage formats on the Revion Retatrutide Pen 40mg Product Page.